{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T00:27:35Z","timestamp":1793147255956,"version":"4.5.0"},"reference-count":67,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T00:00:00Z","timestamp":1748995200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82372892"],"award-info":[{"award-number":["82372892"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82073068"],"award-info":[{"award-number":["82073068"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Beijing Natural Science Foundation Grant","award":["7212056"],"award-info":[{"award-number":["7212056"]}]}],"content-domain":{"domain":["www.plosbiology.org"],"crossmark-restriction":false},"short-container-title":["PLoS Biol"],"abstract":"<jats:p>Indisulam, a sulfonamide-based compound, is employed as a second-line therapy for NSCLC due to its anti-tumor activity. However, its clinical efficacy is hindered by acquired resistance, the molecular basis of which remains poorly understood. Here, we demonstrate that hypermethylation of RNA-binding protein 39 (RBM39), a specific target of Indisulam, is closely associated with Indisulam resistance. PRMT6 methylates RBM39 at R92. This methylation inhibits Indisulam-induced ubiquitination and proteasomal degradation of RBM39, increases RBM39 protein levels, promotes alternative splicing and expression of proto-oncogenes, and ultimately leads to malignant proliferation and metastasis of NSCLC cells and tumor growth in xenograft mouse models. Inhibiting PRMT6 with MS023 or mutating the RBM39 methylation site enhances Indisulam sensitivity in NSCLC and significantly improves its anti-tumor efficacy. Our findings identify methylated RBM39 as a key biomarker of Indisulam resistance and suggest a potential therapeutic strategy for NSCLC.<\/jats:p>","DOI":"10.1371\/journal.pbio.3002846","type":"journal-article","created":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T13:51:52Z","timestamp":1749045112000},"page":"e3002846","update-policy":"https:\/\/doi.org\/10.1371\/journal.pbio.corrections_policy","source":"Crossref","is-referenced-by-count":9,"title":["Methylation of RBM39 by PRMT6 enhances resistance to Indisulam in non-small cell lung cancer by promoting alternative splicing of proto-oncogenes"],"prefix":"10.1371","volume":"23","author":[{"given":"Tongjia","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shujie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zitao","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kejia","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7280-2844","authenticated-orcid":true,"given":"Xiaowei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,6,4]]},"reference":[{"issue":"1","key":"pbio.3002846.ref001","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21708","article-title":"Cancer statistics, 2022","volume":"72","author":"RL Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"pbio.3002846.ref002","doi-asserted-by":"crossref","first-page":"212","DOI":"10.3322\/caac.20121","article-title":"Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths","volume":"61","author":"R Siegel","year":"2011","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"pbio.3002846.ref003","doi-asserted-by":"crossref","first-page":"504","DOI":"10.6004\/jnccn.2017.0050","article-title":"Non-small cell lung cancer, version 5.2017, NCCN clinical practice guidelines in oncology","volume":"15","author":"DS Ettinger","year":"2017","journal-title":"J Natl Compr Canc Netw"},{"issue":"4","key":"pbio.3002846.ref004","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.21037\/jtd.2018.03.143","article-title":"Factors associated with the prognosis and long-term survival of patients with metastatic lung adenocarcinoma: a retrospective analysis","volume":"10","author":"CY Huang","year":"2018","journal-title":"J Thorac Dis"},{"issue":"11","key":"pbio.3002846.ref005","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.3390\/cancers13112603","article-title":"Surgery after induction targeted therapy and immunotherapy for lung cancer","volume":"13","author":"T Allaeys","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"6","key":"pbio.3002846.ref006","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/s41571-018-0002-6","article-title":"The emerging clinical relevance of genomics in cancer medicine","volume":"15","author":"MF Berger","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"pbio.3002846.ref007","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1158\/1078-0432.CCR-06-0249","article-title":"A randomized phase II pharmacokinetic and pharmacodynamic study of indisulam as second-line therapy in patients with advanced non-small cell lung cancer","volume":"13","author":"DC Talbot","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"15","key":"pbio.3002846.ref008","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1200\/JCO.22.02545","article-title":"Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy","volume":"41","author":"FA Shepherd","year":"2023","journal-title":"J Clin Oncol"},{"issue":"2","key":"pbio.3002846.ref009","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa050753","article-title":"Erlotinib in previously treated non-small-cell lung cancer","volume":"353","author":"FA Shepherd","year":"2005","journal-title":"N Engl J Med"},{"issue":"19","key":"pbio.3002846.ref010","doi-asserted-by":"crossref","first-page":"3789","DOI":"10.1021\/jm9902638","article-title":"Discovery of novel antitumor sulfonamides targeting G1 phase of the cell cycle","volume":"42","author":"T Owa","year":"1999","journal-title":"J Med Chem"},{"issue":"3","key":"pbio.3002846.ref011","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1023\/A:1010608317361","article-title":"Mechanisms of action of the novel sulfonamide anticancer agent E7070 on cell cycle progression in human non-small cell lung cancer cells","volume":"19","author":"K Fukuoka","year":"2001","journal-title":"Invest New Drugs"},{"issue":"1","key":"pbio.3002846.ref012","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1093\/annonc\/mdi016","article-title":"Phase II study of E7070 in patients with metastatic melanoma","volume":"16","author":"JF Smyth","year":"2005","journal-title":"Ann Oncol"},{"issue":"9","key":"pbio.3002846.ref013","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1023\/A:1012287111922","article-title":"Phase I and pharmacokinetic study of E7070, a novel sulfonamide, given at a daily times five schedule in patients with solid tumors. A study by the EORTC-early clinical studies group (ECSG)","volume":"12","author":"CJ Punt","year":"2001","journal-title":"Ann Oncol"},{"issue":"16","key":"pbio.3002846.ref014","doi-asserted-by":"crossref","first-page":"3508","DOI":"10.1200\/JCO.2002.09.030","article-title":"Phase I and pharmacokinetic study of E7070, a novel chloroindolyl sulfonamide cell-cycle inhibitor, administered as a one-hour infusion every three weeks in patients with advanced cancer","volume":"20","author":"E Raymond","year":"2002","journal-title":"J Clin Oncol"},{"issue":"14","key":"pbio.3002846.ref015","first-page":"5195","article-title":"Phase I and pharmacokinetic study of E7070, a chloroindolyl-sulfonamide anticancer agent, administered on a weekly schedule to patients with solid tumors","volume":"9","author":"C Dittrich","year":"2003","journal-title":"Clin Cancer Res"},{"issue":"10","key":"pbio.3002846.ref016","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1111\/j.1349-7006.2005.00109.x","article-title":"Phase I pharmacokinetic and pharmacogenomic study of E7070 administered once every 21 days","volume":"96","author":"Y Yamada","year":"2005","journal-title":"Cancer Sci"},{"issue":"2","key":"pbio.3002846.ref017","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.annonc.2021.11.009","article-title":"Open-label phase II study of the efficacy of nivolumab for cancer of unknown primary","volume":"33","author":"J Tanizaki","year":"2022","journal-title":"Ann Oncol"},{"issue":"14","key":"pbio.3002846.ref018","doi-asserted-by":"crossref","first-page":"4680","DOI":"10.1158\/1078-0432.CCR-04-0229","article-title":"A phase II clinical and pharmacodynamic study of E7070 in patients with metastatic, recurrent, or refractory squamous cell carcinoma of the head and neck: modulation of retinoblastoma protein phosphorylation by a novel chloroindolyl sulfonamide cell cycle inhibitor","volume":"10","author":"RI Haddad","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"6336","key":"pbio.3002846.ref019","article-title":"Anticancer sulfonamides target splicing by inducing RBM39 degradation via recruitment to DCAF15","volume":"356","author":"T Han","year":"2017","journal-title":"Science"},{"issue":"6","key":"pbio.3002846.ref020","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/nchembio.2363","article-title":"Selective degradation of splicing factor CAPER\u03b1 by anticancer sulfonamides","volume":"13","author":"T Uehara","year":"2017","journal-title":"Nat Chem Biol"},{"issue":"4","key":"pbio.3002846.ref021","article-title":"CAPER is vital for energy and redox homeostasis by integrating glucose-induced mitochondrial functions via ERR-\u03b1-Gabpa and stress-induced adaptive responses via NF-\u03baB-cMYC","volume":"11","author":"YK Kang","year":"2015","journal-title":"PLoS Genet"},{"issue":"21","key":"pbio.3002846.ref022","doi-asserted-by":"crossref","first-page":"10792","DOI":"10.1128\/JVI.00903-08","article-title":"CAPERalpha is a novel Rel-TAD-interacting factor that inhibits lymphocyte transformation by the potent Rel\/NF-kappaB oncoprotein v-Rel","volume":"82","author":"J Dutta","year":"2008","journal-title":"J Virol"},{"issue":"2","key":"pbio.3002846.ref023","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1074\/jbc.M110417200","article-title":"Molecular cloning and characterization of CAPER, a novel coactivator of activating protein-1 and estrogen receptors","volume":"277","author":"D-J Jung","year":"2002","journal-title":"J Biol Chem"},{"issue":"3","key":"pbio.3002846.ref024","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.molcel.2004.12.025","article-title":"Steroid hormone receptor coactivation and alternative RNA splicing by U2AF65-related proteins CAPERalpha and CAPERbeta","volume":"17","author":"DH Dowhan","year":"2005","journal-title":"Mol Cell"},{"issue":"1","key":"pbio.3002846.ref025","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.bbrc.2016.03.108","article-title":"Functional interaction between nonreceptor tyrosine kinase c-Abl and SR-Rich protein RBM39","volume":"473","author":"S Mai","year":"2016","journal-title":"Biochem Biophys Res Commun"},{"issue":"3","key":"pbio.3002846.ref026","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.ccell.2019.01.010","article-title":"Targeting an RNA-binding protein network in acute myeloid leukemia","volume":"35","author":"E Wang","year":"2019","journal-title":"Cancer Cell"},{"issue":"1","key":"pbio.3002846.ref027","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/s41420-021-00598-7","article-title":"RNA-binding protein 39: a promising therapeutic target for cancer","volume":"7","author":"C Xu","year":"2021","journal-title":"Cell Death Discov"},{"issue":"12","key":"pbio.3002846.ref028","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1111\/bph.15331","article-title":"RNA-binding motif protein 39 (RBM39): an emerging cancer target","volume":"179","author":"Y Xu","year":"2022","journal-title":"Br J Pharmacol"},{"issue":"7","key":"pbio.3002846.ref029","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/s41573-021-00159-8","article-title":"Protein arginine methylation: from enigmatic functions to therapeutic targeting","volume":"20","author":"Q Wu","year":"2021","journal-title":"Nat Rev Drug Discov"},{"issue":"9","key":"pbio.3002846.ref030","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.3390\/cells9091973","article-title":"Fine-Tuning of GLI activity through arginine methylation: its mechanisms and function","volume":"9","author":"Y Abe","year":"2020","journal-title":"Cells"},{"key":"pbio.3002846.ref031","doi-asserted-by":"crossref","first-page":"101016","DOI":"10.1016\/j.drup.2023.101016","article-title":"Promising role of protein arginine methyltransferases in overcoming anti-cancer drug resistance","volume":"72","author":"Y Zhu","year":"2024","journal-title":"Drug Resist Updat"},{"key":"pbio.3002846.ref032","doi-asserted-by":"crossref","first-page":"841381","DOI":"10.3389\/fonc.2022.841381","article-title":"The emerging role of PRMT6 in cancer","volume":"12","author":"Z Chen","year":"2022","journal-title":"Front Oncol"},{"issue":"1","key":"pbio.3002846.ref033","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1038\/s41467-022-28907-3","article-title":"Indisulam targets RNA splicing and metabolism to serve as a therapeutic strategy for high-risk neuroblastoma","volume":"13","author":"A Nijhuis","year":"2022","journal-title":"Nat Commun"},{"issue":"9","key":"pbio.3002846.ref034","doi-asserted-by":"crossref","first-page":"4462","DOI":"10.1021\/acs.jproteome.1c00437","article-title":"Proximity labeling, quantitative proteomics, and biochemical studies revealed the molecular mechanism for the inhibitory effect of Indisulam on the proliferation of gastric cancer cells","volume":"20","author":"J Lu","year":"2021","journal-title":"J Proteome Res"},{"issue":"1","key":"pbio.3002846.ref035","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41389-022-00421-7","article-title":"Methylation of HBP1 by PRMT1 promotes tumor progression by regulating actin cytoskeleton remodeling","volume":"11","author":"J Wang","year":"2022","journal-title":"Oncogenesis"},{"issue":"24","key":"pbio.3002846.ref036","doi-asserted-by":"crossref","first-page":"4835","DOI":"10.1038\/s41388-019-0761-2","article-title":"MDM2 promotes genome instability by ubiquitinating the transcription factor HBP1","volume":"38","author":"Z Cao","year":"2019","journal-title":"Oncogene"},{"issue":"14","key":"pbio.3002846.ref037","doi-asserted-by":"crossref","first-page":"6868","DOI":"10.1073\/pnas.1811028116","article-title":"PTEN arginine methylation by PRMT6 suppresses PI3K-AKT signaling and modulates pre-mRNA splicing","volume":"116","author":"J Feng","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"pbio.3002846.ref038","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s00280-023-04553-4","article-title":"The role of alternative splicing in lung cancer","volume":"92","author":"X Ning","year":"2023","journal-title":"Cancer Chemother Pharmacol"},{"issue":"5","key":"pbio.3002846.ref039","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/nrg2776","article-title":"Alternative splicing and evolution: diversification, exon definition and function","volume":"11","author":"H Keren","year":"2010","journal-title":"Nat Rev Genet"},{"issue":"1","key":"pbio.3002846.ref040","doi-asserted-by":"crossref","first-page":"506","DOI":"10.21037\/tlcr.2020.03.40","article-title":"Epidemiology of stage III lung cancer: frequency, diagnostic characteristics, and survival","volume":"10","author":"A Casal-Mouri\u00f1o","year":"2021","journal-title":"Transl Lung Cancer Res"},{"issue":"1","key":"pbio.3002846.ref041","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/cam4.4946","article-title":"Characteristics and overall survival of patients with early-stage non-small cell lung cancer: a cohort study in Denmark","volume":"12","author":"V Ehrenstein","year":"2023","journal-title":"Cancer Med"},{"issue":"5","key":"pbio.3002846.ref042","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/S0025-6196(11)60735-0","article-title":"Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship","volume":"83","author":"JR Molina","year":"2008","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"pbio.3002846.ref043","doi-asserted-by":"crossref","first-page":"100013","DOI":"10.1016\/j.esmoop.2020.100013","article-title":"Second-line therapy improves overall survival in primary refractory non-small cell lung cancer (NSCLC) patients","volume":"6","author":"SI Rothschild","year":"2021","journal-title":"ESMO Open"},{"issue":"5","key":"pbio.3002846.ref044","doi-asserted-by":"crossref","first-page":"407","DOI":"10.2217\/imt-2018-0193","article-title":"Pembrolizumab plus chemotherapy for first-line treatment of metastatic nonsquamous non-small-cell lung cancer: a network meta-analysis","volume":"11","author":"AM Frederickson","year":"2019","journal-title":"Immunotherapy"},{"issue":"22","key":"pbio.3002846.ref045","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"L Gandhi","year":"2018","journal-title":"N Engl J Med"},{"issue":"6","key":"pbio.3002846.ref046","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1016\/j.celrep.2019.09.079","article-title":"Aryl sulfonamides degrade RBM39 and RBM23 by recruitment to CRL4-DCAF15","volume":"29","author":"TC Ting","year":"2019","journal-title":"Cell Rep"},{"issue":"3","key":"pbio.3002846.ref047","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1002\/ijc.25366","article-title":"Dysregulation of PRMT1 and PRMT6, Type I arginine methyltransferases, is involved in various types of human cancers","volume":"128","author":"M Yoshimatsu","year":"2011","journal-title":"Int J Cancer"},{"issue":"12","key":"pbio.3002846.ref048","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1038\/sj.bjc.6604807","article-title":"The PRMT1 gene expression pattern in colon cancer","volume":"99","author":"K Mathioudaki","year":"2008","journal-title":"Br J Cancer"},{"key":"pbio.3002846.ref049","doi-asserted-by":"crossref","first-page":"102953","DOI":"10.1016\/j.dnarep.2020.102953","article-title":"PRMT1 is critical to FEN1 expression and drug resistance in lung cancer cells","volume":"95","author":"L He","year":"2020","journal-title":"DNA Repair (Amst)"},{"issue":"10","key":"pbio.3002846.ref050","doi-asserted-by":"crossref","first-page":"9010","DOI":"10.18632\/oncotarget.23809","article-title":"The prognostic significance of protein arginine methyltransferase 6 expression in colon cancer","volume":"9","author":"Y Lim","year":"2017","journal-title":"Oncotarget"},{"issue":"5","key":"pbio.3002846.ref051","doi-asserted-by":"crossref","first-page":"84","DOI":"10.4331\/wjbc.v14.i5.84","article-title":"Protein arginine methyltransferase 6 is a novel substrate of protein arginine methyltransferase 1","volume":"14","author":"M-T Cao","year":"2023","journal-title":"World J Biol Chem"},{"issue":"4","key":"pbio.3002846.ref052","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1530\/ERC-12-0100","article-title":"Protein arginine methyltransferase 6-dependent gene expression and splicing: association with breast cancer outcomes","volume":"19","author":"DH Dowhan","year":"2012","journal-title":"Endocr Relat Cancer"},{"issue":"4","key":"pbio.3002846.ref053","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.3892\/ol.2015.3617","article-title":"Effect of phosphorylation and methylation on the function of the p16INK4a protein in non-small cell lung cancer A549 cells","volume":"10","author":"W-L Ma","year":"2015","journal-title":"Oncol Lett"},{"issue":"12","key":"pbio.3002846.ref054","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1016\/j.biocel.2012.09.015","article-title":"Suppression of PRMT6-mediated arginine methylation of p16 protein potentiates its ability to arrest A549 cell proliferation","volume":"44","author":"X Wang","year":"2012","journal-title":"Int J Biochem Cell Biol"},{"issue":"31","key":"pbio.3002846.ref055","doi-asserted-by":"crossref","first-page":"30957","DOI":"10.18632\/oncotarget.5143","article-title":"PRMT6 increases cytoplasmic localization of p21CDKN1A in cancer cells through arginine methylation and makes more resistant to cytotoxic agents","volume":"6","author":"M Nakakido","year":"2015","journal-title":"Oncotarget"},{"issue":"4","key":"pbio.3002846.ref056","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1002\/hep.30923","article-title":"CRAF methylation by PRMT6 regulates aerobic glycolysis-driven hepatocarcinogenesis via ERK-dependent PKM2 nuclear relocalization and activation","volume":"71","author":"T-L Wong","year":"2020","journal-title":"Hepatology"},{"issue":"41","key":"pbio.3002846.ref057","doi-asserted-by":"crossref","first-page":"67532","DOI":"10.18632\/oncotarget.11376","article-title":"Protein arginine methylation\/demethylation and cancer","volume":"7","author":"C Poulard","year":"2016","journal-title":"Oncotarget"},{"issue":"5849","key":"pbio.3002846.ref058","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1126\/science.1145801","article-title":"JMJD6 is a histone arginine demethylase","volume":"318","author":"B Chang","year":"2007","journal-title":"Science"},{"issue":"2","key":"pbio.3002846.ref059","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0087982","article-title":"JMJD6 regulates ER\u03b1 methylation on arginine","volume":"9","author":"C Poulard","year":"2014","journal-title":"PLoS One"},{"issue":"36","key":"pbio.3002846.ref060","doi-asserted-by":"crossref","first-page":"22236","DOI":"10.1074\/jbc.M115.653543","article-title":"Dynamic arginine methylation of tumor necrosis factor (tnf) receptor-associated factor 6 regulates toll-like receptor signaling","volume":"290","author":"I Tikhanovich","year":"2015","journal-title":"J Biol Chem"},{"issue":"16","key":"pbio.3002846.ref061","doi-asserted-by":"crossref","DOI":"10.1016\/j.molcel.2022.06.003","article-title":"An oncogenic JMJD6-DGAT1 axis tunes the epigenetic regulation of lipid droplet formation in clear cell renal cell carcinoma","volume":"82","author":"J Zhou","year":"2022","journal-title":"Mol Cell"},{"issue":"1","key":"pbio.3002846.ref062","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/nrc3409","article-title":"Protein arginine methyltransferases and cancer","volume":"13","author":"Y Yang","year":"2013","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"pbio.3002846.ref063","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.molcel.2016.11.003","article-title":"Arginine methylation: the coming of age.","volume":"65","author":"RS Blanc","year":"2017","journal-title":"Mol Cell"},{"issue":"1","key":"pbio.3002846.ref064","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.molcel.2006.11.019","article-title":"The arginine methyltransferase CARM1 regulates the coupling of transcription and mRNA processing","volume":"25","author":"D Cheng","year":"2007","journal-title":"Mol Cell"},{"issue":"1","key":"pbio.3002846.ref065","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.apsb.2022.05.019","article-title":"PRMT6 promotes tumorigenicity and cisplatin response of lung cancer through triggering 6PGD\/ENO1 mediated cell metabolism","volume":"13","author":"M Sun","year":"2023","journal-title":"Acta Pharm Sin B"},{"issue":"2","key":"pbio.3002846.ref066","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1517\/13543784.12.2.283","article-title":"Indisulam: an anticancer sulfonamide in clinical development","volume":"12","author":"CT Supuran","year":"2003","journal-title":"Expert Opin Investig Drugs"},{"issue":"22","key":"pbio.3002846.ref067","doi-asserted-by":"crossref","first-page":"8252","DOI":"10.1128\/MCB.00604-06","article-title":"The HBP1 transcriptional repressor participates in RAS-induced premature senescence","volume":"26","author":"X Zhang","year":"2006","journal-title":"Mol Cell Biol"}],"container-title":["PLOS Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pbio.3002846","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T13:52:08Z","timestamp":1749045128000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pbio.3002846"}},"subtitle":[],"editor":[{"given":"Hilary A.","family":"Coller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,6,4]]},"references-count":67,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,6,4]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pbio.3002846","relation":{},"ISSN":["1545-7885"],"issn-type":[{"value":"1545-7885","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,4]]}}}